Day One Biopharmaceuticals, Inc.

DAWN

Day One Biopharmaceuticals, Inc.

DAWN

Insider Sentiment (TTM):

Last Purchase:2023-10-20Last Sale:2026-02-17Shares Purchased (TTM):0Shares Sold (TTM):64,462

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:78,576,724Shares Outstanding:103,205,703Institutional Ownership Pct.:76.14%

Earnings Market Reaction:

Filing Date:2026-02-24Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Cash And Cash Equivalents At Carrying Value	197	43	36	33	125	423	240	270	231	241	189	49
Assets Current
Assets Current	485	490	494	509	562	581	383	326	375	413	450	322
Short Term Investments	244	408	417	440	407	136	122	48	136	164	254	269
Receivables Net Current	27	17	20	18	14	9	9	-	0	-	-	-
Inventory Net	6	7	7	4	3	3	0	-	0	-	-	-
Prepaid Expense And Other Assets Current	11	15	15	14	13	11	12	8	9	8	7	4
Property Plant And Equipment Net	2	2	2	3	2	1	0	0	0	0	0	0
Operating Lease Right Of Use Asset	2	2	2	3	2	3	0	0	0	0	1	1
Indefinite Lived Intangible Assets Excluding Goodw…	18	19	20	20	16	16	17	-	0	-	-	-
Assets	508	514	519	534	583	601	400	327	376	414	451	324
Liabilities And Stockhold…
Accounts Payable Current	4	6	5	3	3	3	6	5	3	3	5	5
Accrued Liabilities And Other Liabilities	55	48	44	44	69	35	87	25	27	21	20	18
Liabilities Current
Liabilities Current	61	56	51	48	73	40	94	30	30	24	25	23
Deferred Revenue Current	2	2	2	2	2	1	-	-	0	-	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Noncurrent	3	3	3	3	3	3	-	-	0	-	-	-
Operating Lease Liability Noncurrent	3	3	3	3	3	3	-	-	0	0	0	0
Other Liabilities Noncurrent	0	1	1	1	1	-	-	-	0	-	-	-
Liabilities	67	63	58	55	80	45	94	30	30	25	25	23
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,102	1,091	1,081	1,070	1,057	1,044	832	818	805	794	784	612
Stockholders Equity
Stockholders Equity	441	451	461	480	503	555	307	297	347	390	426	300
Accumulated Other Comprehensive Income Loss Net Of…	0	0	-0	-0	0	-0	-0	-0	0	-0	-0	0
Retained Earnings Accumulated Deficit	-661	-640	-620	-590	-554	-488	-525	-521	-459	-404	-358	-312
Liabilities And Stockholders Equity	508	514	519	534	583	601	400	327	376	414	451	324
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0.001	0.001	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	103	103	102	101	101	101	88	87	87	87	87	74
Shares Outstanding	103	103	102	101	101	101	88	87	87	87	87	74

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	-8.73%	-7.44%	3.43%	9.16%	-1.60%	8.87%	30.00%	29.45%	63.70%	78.30%	78.54%	-
2024	-20.06%	-16.99%	-3.43%	1.22%	6.18%	7.83%	-5.18%	-11.61%	-13.34%	-30.37%	-42.13%	-47.12%
2023	-13.82%	-14.10%	-16.38%	12.93%	-0.81%	-17.78%	0.57%	19.77%	16.57%	-0.64%	-4.41%	3.32%
2022	-	-	-	-	-	-	-	-	-	-27.18%	-32.46%	-32.08%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	8.02	8.68	9.65	10.62	7.66	14.62	4.09	10.93	12.72	16.89	18.35	14.11
Quick Ratio	7.73	8.29	9.23	10.26	7.43	14.27	3.96	10.66	12.42	16.57	18.07	13.93
Working Capital	424.58M	433.51M	443.21M	460.77M	488.88M	541.25M	289.45M	296.20M	345.77M	388.82M	425.27M	299.54M
Leverage & Debt
Debt to Equity	0.15	0.14	0.13	0.11	0.16	0.08	0.31	0.10	0.09	0.06	0.06	0.08
Interest Coverage TTM	-	-	-	-	-	-	-	-	-	-71.16	-38.98	-34.78
Debt Ratio	0.13	0.12	0.11	0.10	0.14	0.08	0.23	0.09	0.08	0.06	0.05	0.07
Efficiency & Turnover
Asset Turnover TTM	0.29	0.24	0.41	0.38	0.27	0.20	0.02	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	47.69	34.67	28.02	40.70	38.61	31.13	407.06	-	-	-	-	-
Receivables Turnover TTM	7.65	10.53	13.03	8.97	9.45	11.73	0.90	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-1,039.88	-1.47	-0.92	-0.67	-1.02	-1.31	-2.41	-2.90	-2.90	-2.03	-2.22	-2.18
Free Cash Flow Per Share TTM	-1.01	-1.17	-0.64	-0.87	-0.86	-0.93	-2.04	-1.97	-1.84	-1.64	-1.70	-1.59
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-82.20%	-123.90%	-59.55%	-118.31%	-165.65%	-207.40%	-3,570.91%	-	-	-	-	-
Net Profit Margin TTM	-69,052.44%	-113.53%	-50.63%	-42.66%	-72.81%	-124.26%	-2,561.93%	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	18.50%	31.11%	2,190.50%	-	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	112,283.76%	19.79%	-54.74%	-72.51%	-58.72%	-27.41%	26.31%	60.26%	62.69%	24.55%	36.69%	56.05%
EPS Growth (1Y)	101,425.49%	11.96%	-61.74%	-76.80%	-64.68%	-35.42%	8.68%	33.07%	33.51%	2.90%	10.79%	26.58%
Calculated Values
Free Cash Flow TTM	-104.08M	-121.36M	-65.52M	-89.87M	-80.28M	-90.24M	-177.37M	-170.80M	-147.08M	-141.01M	-127.12M	-114.33M
Net Debt	-84.82M	-43.28M	-35.62M	-33.36M	-124.97M	-422.77M	-239.62M	-270.39M	-230.78M	-241.18M	-189.21M	-49.27M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-17Sale

Owner: Bender, Jeremy

Title: CHIEF EXECUTIVE OFFICER

Shares: 15,459

Price/Share: $11.60

Value: $179,324.40

Shares Owned: 204,603

Relationship: Director,Officer

Ownership: Direct

2026-02-17Sale

Owner: Dubow, Adam

Title: Gen Counsel & Secretary

Shares: 6,395

Price/Share: $11.60

Value: $74,182.00

Shares Owned: 72,694

Relationship: Officer

Ownership: Direct

2026-02-17Sale

Owner: Merendino, Lauren

Title: Chief Commercial Officer

Shares: 5,814

Price/Share: $11.60

Value: $67,442.40

Shares Owned: 60,157

Relationship: Officer

Ownership: Direct

2026-02-17Sale

Owner: Vasconcelles, Michael

Title: Head of Research and Dev.

Shares: 2,728

Price/Share: $11.60

Value: $31,644.80

Shares Owned: 4,397

Relationship: Officer

Ownership: Direct

2026-02-17Sale

Owner: York, Charles N Ii

Title: COO and CFO

Shares: 6,065

Price/Share: $11.60

Value: $70,354.00

Shares Owned: 312,025

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-17	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	15,459	11.60	$179,324.40	204,603	4
2026-02-17	Dubow, Adam	Officer	Gen Counsel & Secretary	Direct	Sale	6,395	11.60	$74,182.00	72,694	4
2026-02-17	Merendino, Lauren	Officer	Chief Commercial Officer	Direct	Sale	5,814	11.60	$67,442.40	60,157	4
2026-02-17	Vasconcelles, Michael	Officer	Head of Research and Dev.	Direct	Sale	2,728	11.60	$31,644.80	4,397	4
2026-02-17	York, Charles N Ii	Officer	COO and CFO	Direct	Sale	6,065	11.60	$70,354.00	312,025	4
2025-11-17	Dubow, Adam	Officer	Gen Counsel & Secretary	Direct	Sale	4,319	8.91	$38,482.29	62,626	4
2025-11-17	York, Charles N Ii	Officer	COO and CFO	Direct	Sale	4,062	8.91	$36,192.42	294,715	4
2025-11-17	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	15,894	8.91	$141,615.54	177,165	4
2025-11-17	Merendino, Lauren	Officer	Chief Commercial Officer	Direct	Sale	3,726	8.91	$33,198.66	50,809	4
2025-08-18	Dubow, Adam	Officer	Gen Counsel & Secretary	Direct	Sale	4,365	6.77	$29,551.05	54,858	4
2025-08-18	York, Charles N Ii	Officer	COO and CFO	Direct	Sale	4,106	6.77	$27,797.62	278,000	4
2025-08-18	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	16,058	6.77	$108,712.66	161,365	4
2025-08-18	Merendino, Lauren	Officer	Chief Commercial Officer	Direct	Sale	3,766	6.77	$25,495.82	41,931	4
2025-05-16	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	13,964	6.26	$87,414.64	145,737	4
2025-05-16	Dubow, Adam	Officer	GENERAL COUNSEL	Direct	Sale	4,552	6.26	$28,495.52	47,136	4
2025-05-16	York, Charles N Ii	Officer	COO, CFO AND SECRETARY	Direct	Sale	4,282	6.26	$26,805.32	265,231	4
2025-05-16	Merendino, Lauren	Officer	Chief Commercial Officer	Direct	Sale	3,927	6.26	$24,583.02	35,161	4
2025-02-18	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	12,048	11.96	$144,094.08	128,015	4
2025-02-18	York, Charles N Ii	Officer	COO, CFO AND SECRETARY	Direct	Sale	4,370	11.96	$52,265.20	252,638	4
2025-02-18	Dubow, Adam	Officer	GENERAL COUNSEL	Direct	Sale	4,646	11.96	$55,566.16	39,602	4
2024-12-10	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	30,000	13.31	$399,300.00	1,034,015	4
2024-11-18	York, Charles N Ii	Officer	COO, CFO AND SECRETARY	Direct	Sale	2,602	13.21	$34,372.42	240,133	4
2024-11-18	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,554	13.21	$139,418.34	108,377	4
2024-11-18	Dubow, Adam	Officer	GENERAL COUNSEL	Direct	Sale	3,165	13.21	$41,809.65	32,162	4
2024-11-18	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	2,206	13.21	$29,141.26	1,064,015	4
2024-11-11	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	10,000	16.10	$161,000.00	1,057,535	4
2024-11-07	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	11,245	16.03	$180,257.35	1,085,790	4
2024-10-31	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	500	16.02	$8,010.00	1,097,035	4
2024-09-10	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	30,000	14.22	$426,600.00	1,097,535	4
2024-08-16	York, Charles N Ii	Officer	COO, CFO AND SECRETARY	Direct	Sale	2,633	14.00	$36,862.00	232,485	4
2024-08-16	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	2,232	14.00	$31,248.00	1,127,535	4
2024-08-16	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,681	14.00	$149,534.00	98,932	4
2024-08-16	Dubow, Adam	Officer	GENERAL COUNSEL	Direct	Sale	3,202	14.00	$44,828.00	26,928	4
2024-07-16	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	20,000	16.01	$320,200.00	1,121,081	4
2024-06-21	Ramasastry, Saira	Director	-	Direct	Sale	10,000	13.19	$131,900.00	40,485	4
2024-06-10	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	30,000	12.62	$378,600.00	1,141,081	4
2024-05-16	Dubow, Adam	Officer	GENERAL COUNSEL	Direct	Sale	3,253	16.08	$52,308.24	21,731	4
2024-05-16	York, Charles N Ii	Officer	COO, CFO AND SECRETARY	Direct	Sale	2,675	16.08	$43,014.00	224,868	4
2024-05-16	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	2,267	16.08	$36,453.36	1,171,081	4
2024-05-16	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,873	16.08	$126,597.84	654,728	4
2024-05-10	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	10,000	16.37	$163,700.00	1,164,662	4
2024-05-03	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	9,154	17.85	$163,398.90	642,602	4
2024-05-03	York, Charles N Ii	Officer	COO, CFO AND SECRETARY	Direct	Sale	8,078	17.85	$144,192.30	217,293	4
2024-04-18	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	10,000	16.02	$160,200.00	1,174,662	4
2024-03-25	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	10,000	16.01	$160,100.00	1,184,662	4
2024-03-11	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	30,000	15.24	$457,200.00	1,194,662	4
2024-02-27	Blackman, Samuel C.	Officer	HEAD OF R&D	Direct	Sale	20,000	16.11	$322,200.00	1,224,662	4
2024-02-16	York, Charles N Ii	Officer	COO, CFO AND SECRETARY	Direct	Sale	2,666	15.25	$40,656.50	277,754	4
2024-02-16	Bender, Jeremy	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,615	15.25	$116,128.75	721,813	4
2024-02-16	Dubow, Adam	Officer	GENERAL COUNSEL	Direct	Sale	3,242	15.25	$49,440.50	16,585	4
2024-02-16	Blackman, Samuel C.	Officer	HEAD OF RESEARCH AND DEVELOPME	Direct	Sale	2,258	15.25	$34,434.50	1,244,662	4
2023-11-16	York, Charles N Ii	Officer	COO, CFO and Secretary	Direct	Sale	956	11.69	$11,175.64	270,170	4
2023-11-16	Blackman, Samuel C.	Officer	Head of Research and Developme	Direct	Sale	709	11.69	$8,288.21	1,238,234	4
2023-11-16	Dubow, Adam	Officer	General Counsel	Direct	Sale	5,313	11.69	$62,108.97	11,428	4
2023-11-16	Bender, Jeremy	Director,Officer	Chief Executive Officer	Direct	Sale	3,107	11.69	$36,320.83	709,429	4
2023-10-20	Access, Industries Manage…	Other	-	Direct	Purchase	111,387	9.97	$1,110,528.39	12,929,322	4
2023-08-17	Bender, Jeremy	Director,Officer	Chief Executive Officer	Direct	Sale	2,996	13.86	$41,524.56	704,224	4
2023-08-17	York, Charles N Ii	Officer	COO, CFO and Secretary	Direct	Sale	922	13.86	$12,778.92	267,501	4
2023-08-17	Blackman, Samuel C.	Officer	Head of Research and Developme	Direct	Sale	668	13.86	$9,258.48	1,236,319	4
2023-06-09	Blavatnik, Len, Access In…	TenPercentOwner	-	Direct	Purchase	769,230	13.00	$9,999,990.00	11,453,868	4
2023-06-05	Blackman, Samuel C.	Officer	Chief Medical Officer	Direct	Sale	1,229	16.00	$19,664.00	1,234,363	4
2023-05-16	Bender, Jeremy	Director,Officer	Chief Executive Officer	Direct	Sale	3,104	13.12	$40,724.48	1,179,484	4
2023-05-16	Blackman, Samuel C.	Officer	Chief Medical Officer	Direct	Sale	692	13.12	$9,079.04	1,235,592	4
2023-05-16	York, Charles N Ii	Officer	COO, CFO and Secretary	Direct	Sale	955	13.12	$12,529.60	264,798	4
2023-03-10	Blackman, Samuel C.	Officer	Chief Medical Officer	Direct	Sale	10,000	18.05	$180,500.00	1,233,660	4
2023-03-07	Bender, Jeremy	Director,Officer	Chief Executive Officer	Direct	Sale	12,500	20.01	$250,125.00	1,174,276	4
2023-03-01	Grant, Julie Papanek	Director	-	Indirect	Sale	25,000	18.61	$465,250.00	330,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

76.14%

Inst. Shares: 78,576,724

Shares Outstanding: 103,205,703

2025-12-31

77.22%

Inst. Shares: 79,699,104

Shares Outstanding: 103,205,703

2025-09-30

80.72%

Inst. Shares: 83,448,669

Shares Outstanding: 103,381,315

2025-06-30

80.56%

Inst. Shares: 83,036,515

Shares Outstanding: 103,069,154

2025-03-31

89.38%

Inst. Shares: 91,799,141

Shares Outstanding: 102,710,382

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	78,576,724	103,205,703	76.14%
2025-12-31	79,699,104	103,205,703	77.22%
2025-09-30	83,448,669	103,381,315	80.72%
2025-06-30	83,036,515	103,069,154	80.56%
2025-03-31	91,799,141	102,710,382	89.38%
2024-12-31	91,067,255	93,234,195	97.68%
2024-09-30	88,833,285	96,623,123	91.94%
2024-06-30	71,875,408	87,121,310	82.50%
2024-03-31	68,083,527	86,679,282	78.55%
2023-12-31	71,927,970	79,773,004	90.17%
2023-09-30	72,851,861	85,952,501	84.76%
2023-06-30	73,176,363	74,964,878	97.61%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Day One Biopharmaceuticals, Inc. (DAWN) — SEC Financial Statements & Analysis

Day One Biopharmaceuticals, Inc. (DAWN) is a pharmaceutical preparations company, incorporated in DE. Day One Biopharmaceuticals, Inc. trades on Nasdaq as: DAWN. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Day One Biopharmaceuticals, Inc. reported a 18.50% year-over-year revenue growth, a Debt-to-Equity ratio of 0.15x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 18.50%
Debt To Equity: 0.15x

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Day One Biopharmaceuticals, Inc. in?

Day One Biopharmaceuticals, Inc. (DAWN) operates in the Pharmaceutical Preparations industry.

What exchange does DAWN trade on?

Day One Biopharmaceuticals, Inc. (DAWN) trades on the Nasdaq.

Where is Day One Biopharmaceuticals, Inc. incorporated?

Day One Biopharmaceuticals, Inc. is incorporated in DE.